8 research outputs found
Large-scale copy number analysis reveals variations in genes not previously associated with malignant pleural mesothelioma
Malignant pleural mesothelioma (MPM) is an aggressive tumor that is often causally associated with asbestos exposure. Comparative genomic hybridization techniques and arrays demonstrated a complex set of copy number variations (CNVs) in the MPM-genome. These techniques however have a limited resolution, throughput and flexibility compared to next-generation sequencing platforms. In this study, the presence of CNVs in the MPM-genome was investigated using an MPM-cohort (N = 85) for which genomic microarray data are available through 'The Cancer Genome Atlas' (TCGA). To validate these results, the genomes of MPMs and matched normal samples (N = 21) were analyzed using low-pass whole genome sequencing on an 'Illumina HiSeq' platform. CNVs were detected using in-house developed analysis pipelines and frequencies of copy number loss and gain were calculated. In both datasets, losses on chromosomes 1, 3, 4, 6, 9, 13 and 22 and gains on chromosomes 1, 5, 7 and 17 were found in at least 25% and 15% of MPMs, respectively. Besides the well-known MPM-associated genes, CDKN2A, NF2 and BAP1, other interesting cancer-associated genes were listed as frequently involved in a copy number loss (e.g. EP300, SETD2 and PBRM1). Moreover, four cancer-associated genes showed a high frequency of copy number gain in
Recommendations for implementing lung cancer screening with low-dose computed tomography in Europe
Lung cancer screening (LCS) with low-dose computed tomography (LDCT) was
demonstrated in the National Lung Screening Trial (NLST) to reduce mortality from the disease.
European mortality data has recently become available from the Nelson randomised controlled
trial, which confirmed lung cancer mortality reductions by 26% in men and 39â61% in women.
Recent studies in Europe and the USA also showed positive results in screening workers exposed to
asbestos. All European experts attending the âInitiative for European Lung Screening (IELS)ââa
large international group of physicians and other experts concerned with lung cancerâagreed that
LDCT-LCS should be implemented in Europe. However, the economic impact of LDCT-LCS and
guidelines for its effective and safe implementation still need to be formulated. To this purpose, the
IELS was asked to prepare recommendations to implement LCS and examine outstanding issues.
A subgroup carried out a comprehensive literature review on LDCT-LCS and presented findings at
a meeting held in Milan in November 2018. The present recommendations reflect that consensus
was reached
Bringing oncoâinnovation to Europeâs healthcare systems: The potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine
Rapid and continuing advances in biomarker testing are not being matched by uptake in health systems, and this is hampering both patient care and innovation. It also risks costing health systems the opportunity to make their services more efficient and, over time, more economical. The potential that genomics has brought to biomarker testing in diagnosis, prediction and research is being realised, preâeminently in many cancers, but also in an everâwider range of conditionsâ notably BRCA1/2 testing in ovarian, breast, pancreatic and prostate cancers. Nevertheless, the implementation of genetic testing in clinical routine setting is still challenging. Development is impeded by countryârelated heterogeneity, data deficiencies, and lack of policy alignment on standards, approvalâand the role of realâworld evidence in the processâand reimbursement. The acute nature of the problem is compellingly illustrated by the particular challenges facing the development and use of tumour agnostic therapies, where the gaps in preparedness for taking advantage of this innovative approach to cancer therapy are sharply exposed. Europe should already have in place a guarantee of universal access to a minimum suite of biomarker tests and should be planning for an optimum testing scenario with a wider range of biomarker tests integrated into a more sophisticated health system articulated around personalised medicine. Improving healthcare and winning advantages for Europeâs industrial competitiveness and innovation require an appropriate policy frameworkâstarting with an update to outdated recommendations. We show herein the main issues and proposals that emerged during the previous advisory boards organised by the European Alliance for Personalized Medicine which mainly focus on possible scenarios of harmonisation of both oncogenetic testing and management of cancer patients
Recommendations for implementing lung cancer screening with low-dose computed tomography in Europe
Lung cancer screening (LCS) with low-dose computed tomography (LDCT) was demonstrated in the National Lung Screening Trial (NLST) to reduce mortality from the disease. European mortality data has recently become available from the Nelson randomised controlled trial, which confirmed lung cancer mortality reductions by 26% in men and 39â61% in women. Recent studies in Europe and the USA also showed positive results in screening workers exposed to asbestos. All European experts attending the âInitiative for European Lung Screening (IELS)ââa large international group of physicians and other experts concerned with lung cancerâagreed that LDCT-LCS should be implemented in Europe. However, the economic impact of LDCT-LCS and guidelines for its effective and safe implementation still need to be formulated. To this purpose, the IELS was asked to prepare recommendations to implement LCS and examine outstanding issues. A subgroup carried out a comprehensive literature review on LDCT-LCS and presented findings at a meeting held in Milan in November 2018. The present recommendations reflect that consensus was reached
Randomized trial of surgery versus radiotherapy in patients with stage IIIA (N2) non-small-cell lung cancer after a response to induction chemotherapy. EORTC 08941
Combined modality treatment of patients with stage III non-small-cell lung cancer (NSCLC) has recently become widely accepted. Standard combinations are neoadjuvant chemotherapy followed by radiotherapy or concurrent chemotherapy and radiotherapy. The effect of combined modality treatment on survival is dependent on both the efficacy of chemotherapy to eradicate micrometastases and optimal local control. The European Organization for Research and Treatment of Cancer (EORTC) Lung Cancer Cooperative Group has chosen to investigate in a comparative way the side effects and the effect on survival of radiotherapy versus surgery in stage IIIA (N2) NSCLC.SCOPUS: ar.jinfo:eu-repo/semantics/publishe
Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer: a survey of oncologist perceptions
Background: Immune checkpoint-inhibitors (ICIs) are changing outcomes in different cancer settings, notably for patients with non-small-cell lung cancer (NSCLC). There are, however, still important gaps of evidence for clinical practice when using these novel treatments. In this study, we assessed physiciansâ opinion and experience on challenges for clinical practice with ICIs monotherapy in NSCLC. Methods: A survey was conducted on experienced physicians treating patients with NSCLC with ICIs. Two rounds of pilot tests were carried out for validation among a group of experts. Topics under analysis were in relation to treatment of elderly populations, performance status, brain metastases, use of steroids or antibiotics, the effects of gut microbiome, autoimmune diseases, human immunodeficiency virus infection, solid organ transplants, use of anti-programmed cell death protein 1 versus anti-programmed death-ligand 1 drugs, atypical tumour responses, predictors of response, duration of treatment and a final open question on additional relevant challenges. Results: Two hundred and twenty-one answers were collected, including 106 (48%) valid answers from experts for final analysis (physicians who have treated at least 20 patients with NSCLC with ICIs). The vast majority agreed that the selected topics in this study are important challenges ahead and more evidence is needed. Moreover, predictors of response, treating brain metastasis, shorter duration of treatment, the effects of gut microbiome and concomitant use of steroids were voted the most important topics to be further addressed in prospective clinical research. Conclusions: This survey contributed to understanding which are the main challenges for clinical practice with ICIs monotherapy in NSCLC. It can also contribute to guide further clinical research, considering the opinions and experience of those who regularly treat NSCLC patients with ICIs.SCOPUS: ar.jinfo:eu-repo/semantics/publishe
Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT)
INTRODUCTION: Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibition is the preferred first-line treatment of advanced adenocarcinoma of the lung that harbors EGFR activating tyrosine kinase domain mutations. Most data available pertain to Asian populations in which such mutations are more prevalent. We report on the long-term results of first-line treatment with erlotinib in Caucasian patients with advanced adenocarcinoma of the lung that have a somatic EGFR mutation in their tumor.SCOPUS: ar.jinfo:eu-repo/semantics/publishe
Recommendations for implementing lung cancer screening with low-dose computed tomography in Europe
Lung cancer screening (LCS) with low-dose computed tomography (LDCT) was
demonstrated in the National Lung Screening Trial (NLST) to reduce mortality from the disease.
European mortality data has recently become available from the Nelson randomised controlled
trial, which confirmed lung cancer mortality reductions by 26% in men and 39â61% in women.
Recent studies in Europe and the USA also showed positive results in screening workers exposed to
asbestos. All European experts attending the âInitiative for European Lung Screening (IELS)ââa
large international group of physicians and other experts concerned with lung cancerâagreed that
LDCT-LCS should be implemented in Europe. However, the economic impact of LDCT-LCS and
guidelines for its effective and safe implementation still need to be formulated. To this purpose, the
IELS was asked to prepare recommendations to implement LCS and examine outstanding issues.
A subgroup carried out a comprehensive literature review on LDCT-LCS and presented findings at
a meeting held in Milan in November 2018. The present recommendations reflect that consensus
was reached